Andy Woolston

Senior Bioinformatician at The Barts Cancer Institute (BCI)

[Marco Gerlinger @MarcoGerlinger]

Genetic and immune landscape co-evolution in MMR deficient colorectal cancer: Parallel evo, immunologically distinct subtypes & association of CDX2 loss & PDL1 expression in our preprint https://t.co/S6TG1EjAJm > ITH+Darwinian evolution are critical for MMRd biomarker development

[Cancer Discovery @CD_AACR]

Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. https://t.co/bSer4maIjF @Ludwig_Cancer

[Spencer Cox @SpencerJCox]

🧵I know many people are concerned and curious about vaccine effectiveness and breakthrough infections. This IHC data for the last 30 days is stunning. It turns out the raw numbers of breakthrough cases/hospitalizations/deaths don’t tell the whole story. 1/

[Andy Woolston @AndrewWoolston]

In conclusion, we show that mutational signature activity can influence and predict the molecular evolution of cetuximab resistance and PFS in CRC patients. This defines mutational signatures as a new class of cancer evolution biomarkers.

[Andy Woolston @AndrewWoolston]

Our paper “Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer” is out in Nature Ecology and Evolution (https://t.co/idfV8hf14Y). Thanks to @MarcoGerlinger and team at @ICR_London & @royalmarsdenNHS, @nlbigas, @oriol_pich. Tweetorial:

[Andy Woolston @AndrewWoolston]

RAS Q61H mutations only evolved in the ctDNA samples from patients with SBS17b activity in pre-treatment tumour biopsies. Furthermore, SBS17b detection before treatment predicted for significantly shorter progression free survival with cetuximab.

[Marco Gerlinger @MarcoGerlinger]

Cancer is not self-isolating during Covid. Cancer patients are more at risk than ever. Please help restart research into live-saving cancer therapies in our #KickstartICR fundraising appeal at the @ICR_London - https://t.co/tdYkTgpJqR - Thank you!

[Marco Gerlinger @MarcoGerlinger]

COSMIC Mutational Signatures predict specific RAS/EGFR mutations evolving at cetuximab resistance and PFS. Limited impact of adaptive mutability. Our preprint "Mutational Processes Impact the Evolution of Anti-EGFR Antibody Resistance in Colorectal Cancer" https://t.co/MUo5idgW9o

[Marco Gerlinger @MarcoGerlinger]

Our multimarametric immunofluorescence analysis of nearly 500 resected gastric cancers in @JNCI_Now shows and validates a strong association of high memory and (surprisingly) regulatory T cell infiltartes with good outcome. https://t.co/DHnphnhkoY ....

[Marco Gerlinger @MarcoGerlinger]

We need a Higher Scientific Officer/Technician in translational immunotherapy research at the Institute of Cancer Research, London. Check https://t.co/yf1jUHK6Cg if you're interested to work with T-cells (below in red) and organoids (green) to develop better immunotherapies!

[Marco Gerlinger @MarcoGerlinger]

Extreme heterogeneity, large trunks and parallel evolution in MSI gastric cancer. Our study in @NatureComms https://t.co/INefeLtlno Together with high immunotherapy sensitivity, suggests that mutational heterogeneity does not deterr immune recognition when trunks are large

[Marco Gerlinger @MarcoGerlinger]

Impressive heterogeneity and evolvability of MSI gastro-oesophageal cancer in our latest pre-print: https://t.co/oaA6xFcKLn. Fascianting that immunotherapy works in such MSI cancers (https://t.co/hmvIuiJDfq) - despite massive ITH and multiple immuen evasion drivers!

[Marco Gerlinger @MarcoGerlinger]

Our new ultra-sensitive ctDNA sequencing method using UMI error correction is out as a preprint https://t.co/HN4q3X89zZ